GNPX News and Press, Genprex Inc. From 02/07/24

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreem...

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators PR Newswire Reqorsa ® Therapy May Be Potential Treatment for ALK-Positive Lung Cancer Three Collaborators Selected to Present Positive Nonclinical Data on Genprex...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City...

Genprex to Present at Upcoming BIO CEO & Investor Conference Genprex to Present at Upcoming BIO CEO & Investor Conference PR Newswire Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Feb. 6, 2024 /PRNe...

2024-02-05 08:31:42 ET Chenghe Acquisition  ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies  ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer PR Newswire Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024 ...

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 5.5% to $11.665 on volume of 166,461,596 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.1% to $5.075 on volume of 129,958,072 shares Remark Holdings Inc. (MARK) rose 16.2% to $0.593899 on ...

2024-02-02 12:31:34 ET More on Mid-day movers & stocks. CalAmp Corp. (CAMP) Q3 2024 Earnings Call Transcript Kopin: Visionary Leadership Fuels Growth And Market Potential Kopin Corporation (KOPN) Q3 2023 Earnings Call Transcript CalAmp GAAP EPS of -$2.27 ...

2024-02-02 08:02:09 ET Genprex Inc (GNPX) announced stock split at a ratio of 1-for-40 on 2024-02-02 ... Full story available on KlickAnalytics.com

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that on Feb. 2, 2024, the company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.0...